secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0002007919-25-000083
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx reports Q2 net loss of $28.7M; cash $186.6M; key trial data expected Q4 2025
--------------------------------------------------------------------------------

- Net loss of $28.7M ($1.85/share) vs net income of $1.9B in Q2 2024 due to $2B gain from 101 transaction.
- Revenue $1.3M (up from $0.1M); R&D $22.3M (-67% YoY); G&A $6.4M (-93% YoY).
- Cash and equivalents $186.6M at June 30, down from $216.5M at March 31.
- Ozekibart (INBRX-109) Phase 2 chondrosarcoma trial fully enrolled; results expected by late Oct 2025.
- Initial Phase 2 data for INBRX-106 in head/neck cancer + pembrolizumab expected in Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791925000083/0002007919-25-000083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791925000083/inhibrx-20250813.htm
  HTML page:      https://secwatch.observer/filing/0002007919-25-000083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer